Skip to main content

Lawrence Eichenfield, MD

Lawrence Eichenfield, MD

Chief of Pediatric and Adolescent Dermatology
Rady Children's Hospital-San Diego
Vice Chair, Department of Dermatology
Professor of Dermatology and Pediatrics
UC San Diego School of Medicine

Related Videos

How would you summarize the status of the current arsenal for AD and, in particular, the degree to which new systemic therapies are addressing the unmet for long-term disease management in the pediatric and adolescent population?

How would you summarize the status of the current arsenal for AD and, in particular, the degree to which new systemic therapies are addressing the unmet for long-term disease management in the pediatric and adolescent population?

How do you select among systemic agents for moderate-to-severe AD, including systemic immunotherapy with dupilumab? Where does this IL-4/IL-13 inhibitor fit into sequencing of therapy in pediatric and adolescent patients?

How do you select among systemic agents for moderate-to-severe AD, including systemic immunotherapy with dupilumab? Where does this IL-4/IL-13 inhibitor fit into sequencing of therapy in pediatric and adolescent patients?

What is the rationale for deploying a biologic such as dupilumab that inhibits type 2 cytokine signaling? What symptoms—itch, redness, and systemic burden—in pediatric and adolescent patients are ameliorated by targeted inhibition of IL-4 and IL-13?

What is the rationale for deploying a biologic such as dupilumab that inhibits type 2 cytokine signaling? What symptoms—itch, redness, and systemic burden—in pediatric and adolescent patients are ameliorated by targeted inhibition of IL-4 and IL-13?

In light of the recent approval (May 2020) of dupilumab for AD in pediatric patients between the ages of 6 and 11 years of age, can you review the evidentiary basis for this approval based on clinical trials, and the practical implications?

In light of the recent approval (May 2020) of dupilumab for AD in pediatric patients between the ages of 6 and 11 years of age, can you review the evidentiary basis for this approval based on clinical trials, and the practical implications?

What is the prevalence of AD in various age groups and what is the range of clinical phenotypes in the pediatric and adolescent age groups? What is the impact on the individual patient, and how do co-morbidities make management challenging?

What is the prevalence of AD in various age groups and what is the range of clinical phenotypes in the pediatric and adolescent age groups? What is the impact on the individual patient, and how do co-morbidities make management challenging?

Since systemic immunotherapy targeting type 2 cytokine signaling will likely be started in younger pediatric populations, for what duration of therapy do you recommend with cytokine-inhibiting biologics such as dupilumab?

Since systemic immunotherapy targeting type 2 cytokine signaling will likely be started in younger pediatric populations, for what duration of therapy do you recommend with cytokine-inhibiting biologics such as dupilumab?

Can you share a case of a pediatric patient with severe AD, in whom you intensified therapy with dupilumab, and what the outcome was? How did the discussion evolve with the family and what end points were affected after how many months of therapy?

Can you share a case of a pediatric patient with severe AD, in whom you intensified therapy with dupilumab, and what the outcome was? How did the discussion evolve with the family and what end points were affected after how many months of therapy?

What is the rationale and evidence that supports prompt, intensive, severity-of-disease-appropriate management of moderate-to-severe AD in the pediatric and adolescent age group?

What is the rationale and evidence that supports prompt, intensive, severity-of-disease-appropriate management of moderate-to-severe AD in the pediatric and adolescent age group?

Can you describe a patient with AD who has more moderate but persistent disease, who is doing fairly well, with topical treatments, but in whom you felt intensification with a systemic type 2 cytokine-signaling inhibitor was appropriate?

Can you describe a patient with AD who has more moderate but persistent disease, who is doing fairly well, with topical treatments, but in whom you felt intensification with a systemic type 2 cytokine-signaling inhibitor was appropriate?